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Abstract
As the KL-VS haplotype alters secretion and activity of KLOTHO and uric acid (UA) is associated with endothelial dysfunction
and inflammation, their mutual links may contribute tomicroalbuminuria (MA) in patients with type 1 diabetes (T1D). Therefore,
we hypothesize that KL-VS polymorphism could be associated with the prevalence of MA in T1D patients, and KL-VS
polymorphism could modify physiological functions and pathogenic potential of UA. We have examined 350 patients with
T1D. The analysis concerned KL-VS polymorphism along with the concentrations of serum inflammatory markers, indicators of
renal function, blood pressure, and lipid profile. The incidence of KL-VS genotype was lower in a group with MA in comparison
to patients without this condition. Moreover, KL-VS carriers had improved indicators of renal function, lower concentrations of
pro-inflammatory cytokines, and higher levels of anti-inflammatory markers. Simultaneously, among KL-VS carriers serum UA
was negatively correlated with HbA1c, albumin excretion rate, ACR, CRP, TNF-α, total cholesterol, LDL-C and triglycerides,
and positively correlated with HDL-C. Moreover, among wild-type KLOTHO carriers serum, UA was in positive correlation
with creatinine, blood pressure, IL-12 and MCP-1, and in negative correlation with IL-10 and eGFR. Findings of our study
suggest that the functional KL-VS polymorphism is independently associated with MA and the KL-VS genotype protects from
the development of MA, and KL-VS polymorphism may modify physiological functions and pathogenic potential of UA by
altering the levels of HbA1c, inflammatory biomarkers, indicators of renal function, blood pressure, and lipid profile.
Key messages
• We analyzed the KL-VS polymorphism and the UA serum level in patients with T1D.
• The KL-VS polymorphism is independently associated with microalbuminuria.
• The KL-VS alleles protect from the development of microalbuminuria.
• KL-VS polymorphism may modify physiological functions and pathogenic potential of uric acid.
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Introduction
Microalbuminuria (MA), marker of endothelial dysfunction, is
one of the earliest manifestations of diabetic nephropathy (DN),
and its persistence is associatedwith higher risk of cardiovascular
disease (CVD) morbidity and mortality in type 1 diabetes (T1D)
patients [1]. MA serves not only as an indicator of DN risk but
also as a strong predictor of its progression and is often associated
with severe glomerular damage [1].
The KLOTHO gene has been discovered in 1997 when
mice with serendipitous silencing of this gene have developed
premature aging syndrome [2]. KLOTHO is highly expressed
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in kidneys, brain, and to a lesser extent in other organs [3].
KLOTHO exists in at least two forms, the membrane form,
and the soluble secreted form.Membrane KLOTHO functions
as a cofactor in fibroblast growth factor 23 signaling and as
such mediates phosphate homeostasis and vitamin D metabo-
lism [4]. The circulating form of KLOTHO functions as a
hormone that exerts antioxidative, antisenescence, and
antiapoptotic effects [5]. Moreover, KLOTHO deficiency
causes inflammation [6], endothelial dysfunction [7], and vas-
cular calcification [8].
The kidney is commonly recognized as the prominent
tissue source of circulating KLOTHO given that it is the
largest organ that expresses KLOTHO at high levels.
Therefore, it is not surprising that patients in the early
stages of chronic kidney disease already exhibit markedly
reduced KLOTHO in serum [9] and urine [10] samples
with the progressive decrease of the protein concentrations
in more advanced stages. Moreover, KLOTHO has also
been reported to have a protective effect against kidney
injury in the experimental models [9].
Analyses of human KLOTHO polymorphisms have re-
vealed that even slight alterations of the gene can impact both
longevity and disease risk [11]. The most studied polymor-
phism is KL-VS, a specific haplotype in a block of six single
nucleotide polymorphisms (SNPs) in a perfect linkage dis-
equilibrium. This variant, present in approximately 15% of
Caucasians, harbors two mutations in the coding region that
result in amino acid substitutions and subsequent changes in
the protein secretion as well as its catalytic activity [12].
Carrying one copy of the KL-VS haplotype, unlike two, has
been associated with longevity and healthy cardiovascular
functions [13]. On the other hand, individuals bearing two
KL-VS alleles exhibited lower values of systolic blood pres-
sure and pulse pressure in comparison to heterozygous and
wild-type subjects [14].
Serum uric acid (UA) is associated with increased risk of
various clinical conditions such as gout, metabolic syndrome,
chronic kidney disease, diabetes mellitus, and CVD [15].
Different studies suggest that UA is a relevant and indepen-
dent risk factor for developing cardiovascular and kidney dis-
eases including diabetic nephropathy [16, 17]. UA may medi-
ate these effects by inducing inflammation, oxidative stress,
and endothelial dysfunction [18].
As KL-VS haplotype alters secretion and activity of
KLOTHO [19] and UA is associated with endothelial dys-
function and inflammation, their mutual links may contribute
to microalbuminuria in patients with T1D. Therefore, we hy-
pothesize that:
1) KL-VS polymorphism could be associated with the prev-
alence of MA in T1D patients.
2) KL-VS polymorphism could modify physiological func-
tions and pathogenic potential of UA.
Materials and methods
Subjects
The study subjects included 350 Caucasoid adolescent pa-
tients with type 1 diabetes diagnosed according to the
American Diabetes Association criteria [20], recruited from
the Chair and Clinics of Pediatrics, Diabetology and
Endocrinology, Medical University of Gdańsk. Mean age of
patients was 15.3 ± 3.5 years. Patients with coexisting autoim-
mune and/or inflammatory diseases were excluded from the
study. All patients were treated with humanized insulin at
doses of 0.87 ± 0.2 U/kg. At the time of sampling biochemical
measurement of renal function, C-reactive protein (CRP) and
glycated hemoglobin (HbA1c) were monitored.
The urinary albumin excretion (UAE) was expressed as the
average of the three 24 h collections. Cases were classified as
microalbuminuria when in at least two out of three urine sam-
ples, UAE ratio was 30-300 mg/24 h.
Written informed consent was obtained from all individ-
uals enrolled in the study or from a parent or guardian. This
study was approved by the Ethics Committee of the Medical
University of Gdańsk, and the investigation was carried out in
accordance with the principles of the Declaration of Helsinki.
Medical examinations
Systolic and diastolic blood pressures (SBP and DBP, resp.)
were measured using automatic 24 h ambulatory blood pressure
monitoring (ABPM) by the Holter method. All the average
values of the blood pressure were expressed in the centile charts.
Renal function was evaluated by estimated glomerular fil-
tration rate (eGFR), which was estimated by using the
Zappitelli equation: eGFR (ml/min/1.73 m2) = (507.76 ×
e(0.3 × height (cm)))/(serum cystatin C (mg/l)0.635 × serum creati-
nine (μmol/l)0.547) [21].
Methods
Venous blood samples were withdrawn after 12–14 h
overnight fasting. Serum and plasma samples were col-
lected from T1D patients by centrifugation at 500g for
15 min and stored at − 70 °C until analysis.
Concentrations of cytokines and adhesion molecules
were determined using commercial enzyme-linked im-
munosorbent assay kits (R&D Systems, Minneapolis,
MN, USA) according to the manufacturer’s protocol.
Plasma TC, TG, and HDL-C concentrations were
measured in an independent, ISO certified laboratory.
LDL-C was estimated by the Friedewald equation [22].
Genomic DNA from all subjects was isolated from
EDTA-stabilized blood using the EXTRACTME DNA
BLOOD kit (Blirt, Poland). DNA was stored at −
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20 °C until the time of use. Characterization of KL-VS
polymorphism was analyzed as previously described
[23].
Statistical analysis
The results were analyzed using the Statistica, ver. 12
(StatSoft, Inc., USA). Conformation of the allele frequencies
to the Hardy-Weinberg equilibrium proportions was tested by
theχ2 test. The genotypes and allele frequencies of the KL-VS
polymorphism were compared using Fisher’s exact test.
Differences between groups were analyzed by ANOVA for
normally distributed values or the Kruskal–Wallis test for
nonparametric values and by the χ2 Pearson test for dichoto-
mous variables. Correlation between variables was evaluated
using Spearman’s correlation coefficient. To deal with multi-
ple testing, Benjamini-Hochberg’s correction was used for
statistical significance. The level of significance was set at
p ≤ 0.05. A multiple linear regression analysis was undertaken
to determine the independence of KL-VS polymorphism and
uric acid concentration from other variables. Backward mul-
tivariate regression analyses were performed with stepwise
method, using p > 0.10 as removal criterion. Logistic regres-
sion model was used to examine the association between
KLOTHO polymorphism and microalbuminuria.
Results
KLOTHO genotype distribution
The incidence of each genotype in KLOTHO gene and VS
genotype frequency in T1D patients is shown in Table 1.
The frequency for the VS alleles in KL-VS polymorphism
was 0.124 for T1D subjects. The genotype distribution was
in Hardy-Weinberg equilibrium (p = 0.43).
KLOTHO genotypes and clinical characteristics of
patients
Characteristics of T1D patients included in this study differing
in the KL-VS polymorphism are shown in Table 2. There
were no statistically significant differences in sex, age, age
of T1D onset, BMI, HbA1c, serum UA concentration, and
values of blood pressure between subjects with different KL-
VS genotypes. However, individuals with VS genotype had
shorter duration of T1D (p = 0.04), higher eGFR (p = 0.04)
and lower values of albumin excretion rate (p < 0.001), and
albumin to creatinine ratio (ACR, p < 0.001) than their wild-
type counterparts.
Serum concentrations of different variables in
patients with T1D differing in the KL-VS
polymorphism
Table 3 describes the association between KL-VS genotypes
and serum concentrations of different variables in T1D patients.
There was no statistically significant difference in serum con-
centrations of IL-12, creatinine, total cholesterol, HDL-C, and
triglycerides between subjects with different KL-VS genotypes.











n, number of patients
Hardy-Weinberg equilibrium proportions was tested by the χ2 test
Table 2 KL-VS genotypes and selected clinical characteristics in T1D
patients
Clinical parameter KLOTHO p
wt/wt wt/VS
VS/VS
n (%) 270 (77.1) 80 (22.9) –
Sex (male/female) 153/117 41/39 0.39*
Age (years) 15.4 ± 3.5 15.0 ± 3.5 0.29
Age of onset of diabetes (years) 8.6 ± 3.1 8.9 ± 3.1 0.44
Duration of diabetes (years) 6.9 ± 3.3 6.1 ± 2.9 0.04
BMI (kg/m2) 19.0 ± 2.6 18.8 ± 2.7 0.40
HbA1c (%)
(mmol/mol)
8.7 ± 1.8 8.6 ± 1.5 0.40
72 ± 19 70 ± 17
Albumin excretion rate (mg/24 h) 25 ± 18 16 ± 13 < 0.001
eGFR (ml/min/1.73 m2) 119 ± 27 126 ± 26 0.04
ACR (mg/g) 30 ± 21 18 ± 14 < 0.001
Serum uric acid (mg/dl) 3.26 ± 0.55 3.27 ± 0.49 0.89
Systolic blood pressure (mmHg) 115 ± 8 116 ± 7 0.33
Diastolic blood pressure (mmHg) 72 ± 6 73 ± 6 0.06
n, number of patients
Differences were calculated by the ANOVA test. Data are presented as
arithmetic mean ± standard deviation (SD)
*χ2 Pearson test
p, Benjamini-Hochberg’s adjusted p value for differences between ana-
lyzed genotypes: wild-type KLOTHO and KL-VS alleles
Bold p values indicate that the differences are statistically significant
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However, KL-VS carriers had lower concentrations of pro-
inflammatory CRP (p = 0.001), TNF-α (p = 0.02), MCP-1
(p = 0.001), and cystatin C (p = 0.01). Simultaneously, the VS
carriers had increased serum concentrations of anti-
inflammatory IL-10 (p = 0.009) and LDL-C (p = 0.03) when
compared with holders bearing wild type genotype.
KL-VS genotype and microalbuminuria in T1D
patients
The effects of the KL-VS polymorphism onMAwas evaluated
by multiple linear regression analysis including significant var-
iables: sex, inflammatory status of patients (as serum CRP con-
centration), duration of diabetes, uric acid concentration, and
KLOTHO genotype (Table 4). The model revealed that KL-VS
polymorphismwas independently associatedwithMA. To clar-
ify the effect of this polymorphism on MA, we have compared
the distribution of genotypes between individuals with and
without MA. Analysis of the prevalence ofMA in T1D patients
according to KL-VS genotypes is shown in Table 5. None
deviated significantly from the Hardy-Weinberg equilibrium.
Among 350 diabetic cases, 65 patients had microalbuminuria.
The frequency of VS genotype was lower in patients with MA
in comparison to T1D subjects without this complication (0.061
vs. 0.138; p = 0.006). A multivariable logistic regression anal-
yses revealed that KL-VS polymorphism was significantly as-
sociated with MA with the minor VS genotype decreasing the
risk of these conditions. The adjustment for sex, inflammatory
status of patients, and duration of diabetes did not attenuate this
association. The risk of MA in patient carrying VS genotype
was nearly threefold lower than of non-carriers (OR = 0.359;
95% CI = 0.154-0.839; p = 0.02).
Relationship between serum uric acid concentration
and different variables in T1D patients
The results of Spearman’s correlations between serum UA
and different covariates are reported in Table 6.
In KL-VS carriers, a significant negative correlation was
observed between serum UA and HbA1c (p = 0.001). In con-
trast, UA concentration was not associated with HbA1c in the
wild-type KLOTHO genotype patients.
In the wild-type KLOTHO genotype carriers serum, UA
was positively correlated with the indicator of renal function
such as serum creatinine concentration (p < 0.001) and nega-
tively correlated with eGFR (p = 0.03). On the other hand, the
analysis of KL-VS bearing patients revealed that UA concen-
tration was negatively correlated with ACR (p = 0.02).
In the wild-type KLOTHO genotype carriers, a significant
positive correlation was detected between serum UA concen-
tration and systolic (p = 0.04) as well as diastolic (p = 0.02)
blood pressure. In contrast, serum UAwas not associated with
blood pressure values in KL-VS bearing patients.
Only in KL-VS bearing patients serum UA was negatively
correlated with the concentrations of inflammatory bio-
markers such as CRP (p = 0.04) and TNF-α (p = 0.03). On
the other hand, only in the wild-type KLOTHO genotype car-
riers serum UA was positively linked with pro-inflammatory
IL-12 (p = 0.01) and MCP-1 (p = 0.03).
In the wild-type KLOTHO genotype carriers, a significant
negative correlation has been identified between serumUA and
anti-inflammatory IL-10 (p = 0.02). In contrast, UA concentra-
tion was not associated with IL-10 in KL-VS bearing patients.
Serum UA was in negative correlation with the concentra-
tions of total cholesterol (p = 0.03), LDL-C (p = 0.02) and
triglycerides (p = 0.03), and positively correlated with HDL-
C (p = 0.04). These associations were found only in KL-VS
bearing patients.
Table 3 Serum concentrations of different variables in patients with




CRP (mg/l) 2.09 ± 1.85 1.41 ± 0.93 0.001
TNF-α (pg/ml) 1.15 ± 0.94 0.87 ± 0.98 0.02
IL-12 (pg/ml) 1.81 ± 2.08 1.91 ± 1.63 0.69
MCP-1 (pg/ml) 30 ± 8 27 ± 10 0.001
IL-10 (pg/ml) 1.57 ± 2.15 2.38 ± 3.15 0.009
Creatinine (mg/dl) 0.75 ± 0.12 0.73 ± 0.09 0.30
Cystatin C (mg/l) 0.63 ± 0.15 0.58 ± 0.16 0.01
Total cholesterol (mmol/l) 4.48 ± 0.62 4.53 ± 0.73 0.53
HDL-C (mmol/l) 1.42 ± 0.27 1.48 ± 0.23 0.08
LDL-C (mmol/l) 2.45 ± 0.54 2.66 ± 0.66 0.003
Triglycerides (mmol/l) 1.04 ± 0.48 0.95 ± 0.32 0.12
Differences were calculated by the ANOVA test. Data are presented as
arithmetic mean ± standard deviation (SD)
p, Benjamini-Hochberg’s adjusted p value for differences between ana-
lyzed genotypes: wild-type KLOTHO and KL-VS alleles
Bold p values indicate that the differences are statistically significant
Table 4 Multiple linear regression analysis of the parameters associated
with microalbuminuria in T1D patients
Covariates β t p
Sex (male = 1) 0.180 3.504 < 0.001
CRP 0.158 3.022 0.003
Duration of diabetes 0.110 2.136 0.03
KL-VS polymorphism (VS = 1) − 0.123 − 2.383 0.04
Uric acid 0.112 2.189 0.03
R2 = 0.176
Bold p values indicate that the differences are statistically significant
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Discussion
KLOTHO is a good candidate gene for the T1D due to its im-
portance in insulin signaling and inflammation; however, our
previous study [23] demonstrated that KL-VS genotype is not
directly involved in genetic susceptibility to T1D. Despite this,
the functional KL-VS variant of the KLOTHO gene protects
against the development of retinopathy in patients with T1D
and is likely to improve inflammatory status and delay endothe-
lial dysfunction in these subjects [23]. In the present study, we
aimed to evaluate genetic contribution of the KLOTHO KL-VS
variant to the prevalence of MA and its potential influence on
pathophysiological role of UA in T1D adolescents.
We have hypothesized that the KL-VS polymorphism could
be associated with MA in T1D patients, and our results gave
support to this assumption. Multiple regression analysis has
shown that the KL-VS polymorphism was independently asso-
ciated with MA after adjusting for some conventional risk fac-
tors. These findings indicate that KLOTHO genotype plays an
important role in the pathogenesis of MA. We have also ob-
served that the incidence of KL-VS genotype is lower in a group
with MA in comparison to diabetic patients without this condi-
tion. The risk of MA for KL-VS genotype carriers was nearly
threefold lower than for non-carriers. Moreover, KL-VS bearing
patients had improved indicators of renal function such as albu-
min excretion rate, eGFR, ACR, and cystatin C concentration.
Simultaneously, as KL-VS carriers had lower serum concentra-
tions of pro-inflammatory markers (CRP, TNF-α, MCP-1) and
higher anti-inflammatory IL-10 than non-carriers, we can assume
that the KL-VS genotype is associated with weakened inflam-
matory response. From a clinical perspective, the presence of
statistically significant differences between our data sets is of
limited value, but patients with KL-VS genotype are more
privileged than wild-type carriers.
There is a lot of evidence that KLOTHO is an important factor
for cardiorenal health and disease [19, 24, 25]. In individuals
with type 2 diabetes, the concentration of plasma soluble
KLOTHO has been shown to negatively correlate with the de-
velopment of albuminuria and the decline in eGFR [26].
Therefore, soluble KLOTHO concentration in plasma and urine
Table 5 Distribution of KL-VS
genotype and allele frequencies in










Fisher’s exact test OR 95% CI
n % n %
wt/wt 212 74.4 58 89.2 p = 0.006* 0.359 0.154–0.839
wt/VS 67 23.5 6 9.2
VS/VS 6 2.1 1 1.6
VS frequency 0.138 0.061
n, number of patients
OR, odds ratio
95% CI, 95% confidence interval
* Significance between T1D patients with and without microalbuminuria
Bold p values indicate that the differences are statistically significant
Table 6 Correlation coefficients (R) between serum uric acid level and





HbA1c − 0.0736 − 0.3596*
Albumin excretion rate 0.0263 − 0.2338*
Creatinine 0.2450* 0.0981
eGFR − 0.1316* 0.0013
ACR 0.0408 − 0.2573*
Systolic blood pressure 0.1250* 0.0189
Diastolic blood pressure 0.1375* − 0.1008
CRP 0.0499 − 0.2376*
TNF-α 0.0685 − 0.2392*
IL-12 0.1558* 0.0711
MCP-1 0.1344* 0.0131
IL-10 − 0.1405* − 0.0138
Total cholesterol − 0.0228 − 0.2327*
HDL-C − 0.1170 0.2374*
LDL-C 0.0497 − 0.2535*
Triglycerides − 0.0588 − 0.2462*
The Spearman test was used to calculate the strength of correlation
*Benjamini-Hochberg’s adjusted p < 0.05 for differences between ana-
lyzed genotypes: wild-type KLOTHO and KL-VS alleles
Bold indicate that the differences are statistically significant
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samples may be a novel and useful marker of early diabetic renal
injury [27]. Meanwhile, little is known about the role of
KLOTHO in patients with T1D. In individuals with T1D, MA
has been associated with soluble KLOTHO deficiency [28].
Furthermore, serum KLOTHO may have a protective effect
against atherosclerosis and endothelial dysfunction in these sub-
jects [29]. That is why further analyses are required to determine
the role of KLOTHO in patients with T1D.
Many studies have explored the relationship between
UA and diabetic kidney disease. It has been demonstrat-
ed that in T1D subjects, serum UA is associated with
microvascular endothelial dysfunction [30], development
of micro- and macroalbuminuria [31], and nephropathy
[32]. High serum UA concentrations are also directly
associated with the development and progression of
chronic kidney disease and increased rates of kidney
function loss among T1D patients [33]. UA cannot
work only as an agent of endothelial dysfunction and
kidney disease, but also it influences the cardiorenal
etiology and risk factors. We have found such associa-
tions, depending on sex, among T1D patients [34]. In
the present study, we have observed similar differences
in correlations of serum UA with inflammatory bio-
markers and kidney function between wild-type carriers
and KL-VS bearing patients. We have shown that in
subjects with KL-VS genotype serum, UA was nega-
tively correlated with HbA1c, the indicators of renal
function (albumin excretion rate, ACR), the subclinical
inflammatory markers (CRP, TNF-α), and the lipid pa-
rameters (total cholesterol, LDL-C, triglycerides) as well
as positively correlated with HDL-C. Moreover, in pa-
tients with wild-type KLOTHO genotype serum UA was
positively correlated with creatinine, blood pressure, and
pro-inflammatory factors (IL-12, MCP-1) as well as
negatively correlated with anti-inflammatory IL-10 and
eGFR. Therefore, patients with KL-VS polymorphism
are probably more privileged than their wild-type
counterparts.
KLOTHO is not only involved in longevity and ag-
ing, but it is also a cardiorenal protective factor which
has a central impact on renal physiology and pathophys-
iology. Recent advances in understanding KLOTHO bi-
ology definitely support the notion that aberrant func-
tion of the protein promotes nephropathy progression
and CVD development. The molecular mechanisms of
KLOTHO’s reno- and cardio-protection are still being
unraveled. Despite many genetic association studies on
the KL-VS polymorphism, there is a limited information
on the molecular mechanism behind the KL-VS associ-
ation with renal physiology and pathophysiology. Given
the decreased risk of MA development and inflamma-
tion, a thorough description of the alterations associated
with KLOTHO polymorphism is important for
understanding the role of KLOTHO in diabetic patients.
To our knowledge, the current study for the first time
provides new insights into the pathophysiological link-
age between KL-VS polymorphism, serum UA, and re-
nal function markers as well as some cardiometabolic
risk factors in T1D young patients, although the detailed
molecular mechanisms underlying observed KLOTHO
genotype differences remain to be explored.
The present study has several strengths and limita-
tions that need to be addressed briefly. The strengths
include the use of a pure Caucasoid population from
the north region of Poland to eliminate false positive
results due to population stratification. Moreover, all of
the enrolled patients had relatively preserved renal func-
tion (eGFR > 70), a similar duration of diabetes, and
comprised well-characterized cohort attending a single
center for their diabetes care. Regarding limitations,
firstly, although the study cohort is homogenous and
well-characterized, it may be considered relatively small.
Secondly, despite having detected KLOTHO genotype-
based differences in the correlations between UA con-
centration and inflammatory biomarkers as well as kid-
ney function, there are still many unmeasured genetic
and environmental factors that influence these associa-
tions. Thirdly, our statistical power to assess the corre-
lation of serum UA and measured values was limited.
Finally, we have not measured serum and urinary
KLOTHO concentrations—it is an impediment to inter-
pret observed relationships and their biological signifi-
cance. In spite of these limitations, our findings empha-
size the role of KL-VS polymorphism in patients with
T1D.
In conclusion, findings of our study suggest that:
1) The functional KL-VS polymorphism is independently
associated with MA in such manner that the KL-VS ge-
notype protects against the development of MA in ado-
lescents with T1D.
2) KL-VS polymorphism may modify physiological func-
tions and pathogenic potential of UA by altering the
levels of HbA1c, inflammatory biomarkers, indicators
of renal function, blood pressure, and lipid profile.
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